During the past decade, CRLC Val d'Aurelle Paul-Lamarque conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 6 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CRLC Val d'Aurelle Paul-Lamarque" #1 sponsor was "Institut du Cancer de Montpellier - Val d'Aurelle" with 8 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "UNICANCER" with 4 trials sponsored, "Centre Hospitalier Universitaire de Nīmes" with 3 trials sponsored and "Centre Leon Berard" with 3 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CRLC Val d'Aurelle Paul-Lamarque" #1 collaborator was "National Cancer Institute, France" with 3 trials as a collaborator, "Novartis" with 2 trials as a collaborator, "Fondation ARC" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "Keyrus Biopharma" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "CRLC Val d'Aurelle Paul-Lamarque" are "Breast Cancer" (7 trials), "Adenocarcinoma" (2 trials), "Colorectal Cancer" (2 trials), "Parastomal Hernia" (2 trials) and "Adenocarcinoma of the Prostate" (1 trials). Many other conditions were trialed in "CRLC Val d'Aurelle Paul-Lamarque" in a lesser frequency.

Most popular intervention types in "CRLC Val d'Aurelle Paul-Lamarque" are "Drug" (24 trials), "Procedure" (6 trials), "Other" (4 trials), "Radiation" (4 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "Placebo" (3 trials), "Carboplatin" (2 trials), "Ipatasertib" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "CRLC Val d'Aurelle Paul-Lamarque" are 26 trials for "All" genders, 9 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "CRLC Val d'Aurelle Paul-Lamarque". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in CRLC Val d'Aurelle Paul-Lamarque, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in CRLC Val d'Aurelle Paul-Lamarque, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".